AMAG Pharmaceuticals Announces Appointment of Ricardo Zayas as Senior Vice President of Operations


LEXINGTON, Mass.–(BUSINESS WIRE)– AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on treating iron deficiency anemia and developing novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced that Ricardo Zayas has been appointed Senior Vice President of Operations. Mr. Zayas brings over two decades of pharmaceutical operations and commercial manufacturing experience to the Company. In his new position with AMAG, Mr. Zayas will be responsible for leading the Company’s manufacturing, materials management, quality assurance, quality control, and supply chain functions and will report directly to Brian J.G. Pereira, MD, President and CEO.

“Ricardo’s extensive pharmaceutical manufacturing experience will be invaluable as we prepare to launch and commercialize Feraheme(TM) (ferumoxytol injection),” commented Dr. Pereira. “Ricardo has successfully led manufacturing organizations for several large pharmaceutical companies and has a proven track record of working closely and successfully with government agencies including the FDA. The addition of Ricardo further strengthens our management team as we continue our transition to a commercial biopharmaceutical company.”

Prior to joining AMAG, Mr. Zayas was Vice President and General Manager of Operations at Wyeth Pharmaceuticals in Puerto Rico since 2007, where he was responsible for pharmaceutical product manufacturing operations, with more than 900 employees. Additionally, Mr. Zayas participated in the development of a greenfield vaccine and biotech manufacturing facility in Puerto Rico. Before joining Wyeth, Mr. Zayas spent more than five years at Schering-Plough Corporation in Puerto Rico as General Manager of Operations and Manufacturing, where he was responsible for four separate facilities, including a pharmaceutical manufacturing facility and a chemical manufacturing facility. Earlier in his career Mr. Zayas was with Warner Lambert, where he held positions of increasing responsibility in operations, including managing the oral contraceptive manufacturing facility in Puerto Rico. Mr. Zayas received his B.S. in industrial engineering from Kansas State University.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Feraheme (TM) (ferumoxytol injection) is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease.

    Source: AMAG Pharmaceuticals, Inc.

Contact: AMAG Pharmaceuticals, Inc. Kristen Galfetti, 617-498-3362